Rob C Aalberse1, Christoph Grüber2, Margaretha Ljungman3, Suzan Kakat2, Ulrich Wahn2, Bodo Niggemann2, Lennart J Nilsson4. 1. Amsterdam and Landsteiner Laboratory, Department of Immunopathology, Academic Medical Center, Sanquin Research, University of Amsterdam, Amsterdam, The Netherlands. 2. Department of Pediatric Pneumology and Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany. 3. Health Agency of Sweden, Solna, Sweden. 4. Department of Clinical and Experimental Medicine, Allergy Center, Linköping University, Linköping, Sweden.
Abstract
BACKGROUND: It has previously been shown in an uncontrolled study that the IgE response to vaccine antigens is downregulated by co-vaccination with cellular Bordetella pertussis vaccine. METHODS: In the present study, we compared in a controlled trial the humoral immune response to diphtheria toxoid (D) and tetanus toxoid (T) in relation to co-vaccinated cellular or acellular B pertussis vaccine. IgE, IgG4, and IgG to D and T were analyzed at 2, 7, and 12 months of age in sera of children vaccinated with D and T (DT, N = 68), cellular (DTPw, N = 68), 2- or 5-component acellular B pertussis vaccine (DTPa2, N = 64; DTPa5, N = 65). RESULTS: One month after vaccination, D-IgE was detected in 10% sera of DTPw-vaccinated children, whereas vaccination in the absence of whole-cell pertussis resulted in 50%-60% IgE positivity. Six months after vaccination, the IgE antibody levels were found to be more persistent than the IgG antibodies. These diphtheria findings were mirrored by those for tetanus. Only minor differences between vaccine groups were found with regard to D-IgG and T-IgG. No immediate-type allergic reactions were observed. CONCLUSION: Cellular (but not acellular) B pertussis vaccine downregulates IgE to co-vaccinated antigens in infants. We assume that the absence of immediate-type allergic reactions is due to the high levels of IgG antibodies competing with IgE antibodies.
RCT Entities:
BACKGROUND: It has previously been shown in an uncontrolled study that the IgE response to vaccine antigens is downregulated by co-vaccination with cellular Bordetella pertussis vaccine. METHODS: In the present study, we compared in a controlled trial the humoral immune response to diphtheria toxoid (D) and tetanus toxoid (T) in relation to co-vaccinated cellular or acellular B pertussis vaccine. IgE, IgG4, and IgG to D and T were analyzed at 2, 7, and 12 months of age in sera of children vaccinated with D and T (DT, N = 68), cellular (DTPw, N = 68), 2- or 5-component acellular B pertussis vaccine (DTPa2, N = 64; DTPa5, N = 65). RESULTS: One month after vaccination, D-IgE was detected in 10% sera of DTPw-vaccinated children, whereas vaccination in the absence of whole-cell pertussis resulted in 50%-60% IgE positivity. Six months after vaccination, the IgE antibody levels were found to be more persistent than the IgG antibodies. These diphtheria findings were mirrored by those for tetanus. Only minor differences between vaccine groups were found with regard to D-IgG and T-IgG. No immediate-type allergic reactions were observed. CONCLUSION: Cellular (but not acellular) B pertussis vaccine downregulates IgE to co-vaccinated antigens in infants. We assume that the absence of immediate-type allergic reactions is due to the high levels of IgG antibodies competing with IgE antibodies.
Authors: Gladymar Perez Chacon; Jessica Ramsay; Christopher G Brennan-Jones; Marie J Estcourt; Peter Richmond; Patrick Holt; Tom Snelling Journal: Cochrane Database Syst Rev Date: 2021-09-06
Authors: Ricardo da Silva Antunes; Ferran Soldevila; Mikhail Pomaznoy; Mariana Babor; Jason Bennett; Yuan Tian; Natalie Khalil; Yu Qian; Aishwarya Mandava; Richard H Scheuermann; Mario Cortese; Bali Pulendran; Christopher D Petro; Adrienne P Gilkes; Lisa A Purcell; Alessandro Sette; Bjoern Peters Journal: JCI Insight Date: 2021-04-08
Authors: Gladymar Perez Chacon; Marie J Estcourt; James Totterdell; Dianne E Campbell; Kirsten P Perrett; Julie A Marsh; Peter C Richmond; Nicholas Wood; Michael S Gold; Patrick G Holt; Claire S Waddington; Thomas L Snelling Journal: BMJ Open Date: 2020-12-17 Impact factor: 3.006